Postoperative Hematoma Expansion in Patients Undergoing Decompressive Hemicraniectomy for Spontaneous Intracerebral Hemorrhage.
anticoagulant/antiplatelet medication
decompressive hemicraniectomy
intracerebral bleeding
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
26 Sep 2022
26 Sep 2022
Historique:
received:
15
08
2022
revised:
15
09
2022
accepted:
20
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Introduction: The aim of the study was to analyze risk factors for hematoma expansion (HE) in patients undergoing decompressive hemicraniectomy (DC) in patients with elevated intracranial pressure due to spontaneous intracerebral hematoma (ICH). Methods: We retrospectively evaluated 72 patients with spontaneous ICH who underwent DC at our institution. We compared the pre- and postoperative volumes of ICH and divided the patients into two groups: first, patients with postoperative HE > 6 cm3 (group 1), and second, patients without HE (group 2). Additionally, we screened the medical history for anticoagulant and antiplatelet medication (AC/AP), bleeding-related comorbidities, age, admission Glasgow coma scale and laboratory parameters. Results: The rate of AC/AP medication was higher in group 1 versus group 2 (15/16 vs. 5/38, p < 0.00001), and patients were significantly older in group 1 versus group 2 (65.1 ± 16.2 years vs. 54.4 ± 14.3 years, p = 0.02). Furthermore, preoperative laboratory tests showed lower rates of hematocrit (34.1 ± 5.4% vs. 38.1 ± 5.1%, p = 0.01) and hemoglobin (11.5 ± 1.6 g/dL vs. 13.13 ± 1.8 g/dL, p = 0.0028) in group 1 versus group 2. In multivariate analysis, the history of AC/AP medication was the only independent predictor of HE (p < 0.0001, OR 0.015, CI 95% 0.001−0.153). Conclusion: We presented a comprehensive evaluation of risk factors for hematoma epansion by patients undergoing DC due to ICH.
Identifiants
pubmed: 36291232
pii: brainsci12101298
doi: 10.3390/brainsci12101298
pmc: PMC9599268
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Neurol. 2019 Jan 15;9:1186
pubmed: 30697186
Front Neurol. 2020 Jul 17;11:702
pubmed: 32765408
J Am Heart Assoc. 2019 May 7;8(9):e012023
pubmed: 31046504
Crit Care. 2009;13(6):R185
pubmed: 19930556
J Neurosurg. 2019 Apr 26;132(5):1623-1635
pubmed: 31026834
Stroke. 2015 Jul;46(7):2032-60
pubmed: 26022637
J Neurotrauma. 2008 May;25(5):503-12
pubmed: 18346002
Cerebrovasc Dis. 2016;42(3-4):155-69
pubmed: 27110940
Stroke. 2007 Sep;38(9):2506-17
pubmed: 17690311
Neurosurg Rev. 2018 Apr;41(2):649-654
pubmed: 28956193
Neurosurg Rev. 2021 Jun;44(3):1401-1409
pubmed: 32494988
Lancet Neurol. 2009 Apr;8(4):326-33
pubmed: 19269254
J Neurosurg. 1996 Nov;85(5):853-9
pubmed: 8893724
Lancet Neurol. 2012 Jan;11(1):101-18
pubmed: 22172625
Lancet Neurol. 2012 Apr;11(4):307-14
pubmed: 22405630
Eur J Neurol. 2013 Sep;20(9):1277-83
pubmed: 23647568
Stroke. 1995 Feb;26(2):259-64
pubmed: 7831699
Drugs Aging. 2021 Jul;38(7):611-623
pubmed: 33880747
J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1330-1335
pubmed: 27178897
Neurocrit Care. 2016 Feb;24(1):6-46
pubmed: 26714677
Int J Biomed Imaging. 2018 Jun 3;2018:5237693
pubmed: 29971096
J Neurosurg. 2011 Apr;114(4):954-60
pubmed: 20113157
Int J Stroke. 2018 Aug;13(6):612-632
pubmed: 29786478
N Engl J Med. 2005 Feb 24;352(8):777-85
pubmed: 15728810
Neurosurg Focus. 2013 May;34(5):E5
pubmed: 23634924
Stroke. 2012 Dec;43(12):3207-11
pubmed: 23111437
Stroke. 2010 Sep;41(9):2108-29
pubmed: 20651276
JAMA Neurol. 2016 Aug 1;73(8):961-8
pubmed: 27323314
Crit Care Med. 2020 Jul;48(7):1009-1017
pubmed: 32304415
Stroke. 1997 Jan;28(1):1-5
pubmed: 8996478
Eur J Trauma Emerg Surg. 2022 Jun;48(3):2449-2457
pubmed: 34605961
J Neurotrauma. 2005 Jun;22(6):623-8
pubmed: 15941372
Front Neurol. 2018 Nov 20;9:977
pubmed: 30524359